Arnaud D Kaze1, Prasanna Santhanam2, Sebhat Erqou3, Alain G Bertoni4, Rexford S Ahima2, Justin B Echouffo-Tcheugui5. 1. Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins School of Medicine, Baltimore, MD, USA. 2. Department of Medicine, University of Maryland Medical Center, Baltimore, MD, USA. 3. Department of Medicine, Providence VA Medical Center and Alpert Medical School of Brown University, Providence, RI, USA. 4. Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA. 5. Department of Medicine, University of Maryland Medical Center, Baltimore, MD, USA. Electronic address: jechouf1@jhmi.edu.
Abstract
AIM: To evaluate the associations of microvascular disease (MVD) with incident cardiovascular disease (CVD) in individuals with type 2 diabetes. METHODS: A total of 4098 participants with type 2 diabetes and without CVD were assessed for MVD (diabetic kidney disease, retinopathy or neuropathy) in the Look AHEAD (Action for Health in Diabetes) study. Cox models were used to generate hazard ratios (HRs) for: (1) CVD composite (myocardial infarction, stroke, hospitalization for angina and/or death from cardiovascular causes), (2) coronary artery disease (CAD), (3) stroke, and (4) CVD-related deaths. RESULTS: Of 4098 participants, 34.7% (n = 1424) had MVD at baseline. Over a median of 9.5 years, 487 developed the CVD composite, 410 CAD events, 100 stroke, and 54 CVD-related deaths. After adjusting for relevant confounders, MVD was associated with increased risks of CVD composite (HR 1.34, 95% CI 1.11-1.61), CAD (HR 1.24, 95% CI 1.01-1.52), stroke (HR 1.55, 95% CI 1.03-2.33), and cardiovascular mortality (HR 1.26, 95% CI 0.72-2.22). HRs for CVD composite by type of MVD were 1.11 (95% CI 0.89-1.38), 1.63 (95% CI 1.22-2.17) and 1.16 (95% CI 0.92-1.46) for diabetic kidney disease, retinopathy, and neuropathy, respectively. CONCLUSIONS: Our findings underscore the relevance of MVD in CVD risk assessment in type 2 diabetes.
AIM: To evaluate the associations of microvascular disease (MVD) with incident cardiovascular disease (CVD) in individuals with type 2 diabetes. METHODS: A total of 4098 participants with type 2 diabetes and without CVD were assessed for MVD (diabetic kidney disease, retinopathy or neuropathy) in the Look AHEAD (Action for Health in Diabetes) study. Cox models were used to generate hazard ratios (HRs) for: (1) CVD composite (myocardial infarction, stroke, hospitalization for angina and/or death from cardiovascular causes), (2) coronary artery disease (CAD), (3) stroke, and (4) CVD-related deaths. RESULTS: Of 4098 participants, 34.7% (n = 1424) had MVD at baseline. Over a median of 9.5 years, 487 developed the CVD composite, 410 CAD events, 100 stroke, and 54 CVD-related deaths. After adjusting for relevant confounders, MVD was associated with increased risks of CVD composite (HR 1.34, 95% CI 1.11-1.61), CAD (HR 1.24, 95% CI 1.01-1.52), stroke (HR 1.55, 95% CI 1.03-2.33), and cardiovascular mortality (HR 1.26, 95% CI 0.72-2.22). HRs for CVD composite by type of MVD were 1.11 (95% CI 0.89-1.38), 1.63 (95% CI 1.22-2.17) and 1.16 (95% CI 0.92-1.46) for diabetic kidney disease, retinopathy, and neuropathy, respectively. CONCLUSIONS: Our findings underscore the relevance of MVD in CVD risk assessment in type 2 diabetes.
Authors: P C Y Tong; A P Kong; W Y So; X Yang; M C Y Ng; C S Ho; R C W Ma; R Ozaki; V Ng; C C Chow; C W K Lam; J C N Chan; C S Cockram Journal: Diabet Med Date: 2007-04-02 Impact factor: 4.359
Authors: G Bruno; F Merletti; G Bargero; G Novelli; D Melis; A Soddu; M Perotto; G Pagano; P Cavallo-Perin Journal: Diabetologia Date: 2007-03-02 Impact factor: 10.122
Authors: Donna H Ryan; Mark A Espeland; Gary D Foster; Steven M Haffner; Van S Hubbard; Karen C Johnson; Steven E Kahn; William C Knowler; Susan Z Yanovski Journal: Control Clin Trials Date: 2003-10
Authors: Xilin Yang; Ronald C Ma; Wing-Yee So; Gary T Ko; Alice P Kong; Christopher W Lam; Chun-Shun Ho; Clive S Cockram; Vivian C Wong; Peter C Tong; Juliana C Chan Journal: Cardiovasc Diabetol Date: 2007-12-02 Impact factor: 9.951